[Hyperthermic immuno-cellular therapy-basic and clinical study]

BASIC: We treated mice inoculated LLC tumors with hyperthermia or activated lymphocytes. Both of hyperthermia and activated lymphocytes therapy reduced not only a tumor growth but also lung metastasis. And a combination therapy of hyperthermia and activated lymphocytes therapy reduced more of the tumor growth and lung metastasis synergistically. CLINICAL: We proceeded with hyperthermia (HT) for 472 cancer patients and activated lymphocytes (CAT) therapy for 384 patients and dendritic cell (DC) therapy for 94 patients. Two-hundred-thirty-eight patients of them underwent a combination therapy with hyperthermia and CAT therapy. And 92 patients received a combination therapy with hyperthermia and DC therapy. We proceeded with hyperthermia or immunotherapy for 526 cancer patients. And we have 67 clinical benefit cases including 8 complete response (CR) cases. These basic and clinical results indicate an effectiveness of a combination therapy with hyperthermia and cellular-immunotherapy for cancer patients.